Event Participants
Executives
4 Aman Anavkar, Ashwani Singh, Chirag Doshi, Karan Doshi
Analysts
8 Chandrashekhar Daga, Diya Jain, Niraj Chhajer, Nirav, Raju Pathak, Santosh, Vikas Gupta, Vignesh Iyer
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹74.98 crores | +10.3% YoY from ₹68.01 crores in Q1 FY26; Q1 seasonally light due to H2-weighted EPC milestone recognition |
| Consolidated Net Profit | ₹4.21 crores | Swing from net loss of ₹6.13 crores in Q1 FY26; driven by margin expansion and geographic mix shift |
| EBITDA | ₹7.41 crores (9.0% margin) | Recovery from negative EBITDA of ₹5.27 crores in Q1 FY26; 910 bps contribution margin expansion |
| Contribution Margin | 46.7% | +910 bps YoY from 37.6%; driven by shift to higher-value markets (Saudi, Africa) and procurement efficiency |
| Cost of Goods Sold | ₹41.62 crores | -3.35% YoY despite 10% revenue growth; reflects favorable project/geography mix |
| Finance Cost | ₹0.86 crore | -36% YoY from ₹1.34 crores; efficient working capital use and IPO proceeds deployment |
| Open Order Book | ₹900+ crores | As of June 30, 2026; net of ₹96.5 crores new intake and ₹75 crores execution in Q1 |
| Active Inquiries (Pipeline) | ₹9,300+ crores | Total addressable funnel tracked across geographies |
| Hot Leads (Advanced Funnel) | ₹3,800+ crores | Opportunities at advanced commercial/technical stages with defined conversion path |
| New Order Intake (Q1) | ₹96.5 crores | Includes ₹31.23 crore Botswana veterinary vaccine facility; several large orders delayed not cancelled |
| Trade Receivables | ₹215 crores | Up from ₹211 crores at March-end; mostly LC/CAD backed with 10-15% retention (1-2 year) |
| Customer Advances | ₹110 crores | Offsets receivables; advances received on contracted orders |
| Working Capital Cycle | ~120 days | Normalized cycle; ₹20-22 crores goods stuck at port due to shipment availability constraints |
Geographic & Segment Commentary
Saudi Arabia: Revenue surged 130% YoY to ₹17.14 crores. Incorporated Specialized Contracting Activities LLC (51% stake) providing licensed local platform for MEP/civil infrastructure beyond pharma cleanrooms. Local entity changes tender eligibility under Vision 2030 localization mandates. Approved ₹24 crore capital injection into Fabtech Technologies LLC to support larger bids. One civil order already secured post-acquisition.
Africa (Morocco & Kenya): Combined contribution of ₹27.94 crores from near-zero base a year ago. Engaged with national vaccine institutes, DFI-backed health programs, and private pharma groups building first-of-kind sterile/biologics capacity. Secured ₹31.23 crore Botswana veterinary vaccine project. Structural decade-long local manufacturing shift across continent positions Fabtech as execution partner of choice.
UAE (FTS Segment): Faced genuine regional headwinds from Middle East conflict; focused on high-tech facilities (cell/gene therapy, medical device testing, compounding pharmacies) rather than generic pharma. Large pharma projects in hot pipeline delayed but not cancelled due to geopolitical volatility. UAE remains strategic reference hub showcasing full facility portfolio to visiting international clients.
India: Single specific contract only; not a focus market. 78% of revenue from MENA/GCC/ECO/Persian Gulf. Separate entity (Fabtech Cleanrooms) addresses domestic cleanroom/HVAC market across pharma, data centers, solar, semiconductors.
Company-Specific & Strategic Commentary
Localization Strategy ("Becoming Local"): Majority-owned Saudi entity (Specialized Contracting Activities LLC) transforms Fabtech from specialist subcontractor to prime bidder for MEP/civil infrastructure. Early design engagement protects contribution margin by shaping specifications. Local presence now a hard qualification criterion, not preference, under Saudi Vision 2030. Parallel track: organic local platform + inorganic capability acquisition.
Inorganic Growth - Italy & Saudi Acquisitions: Business due diligence underway for both targets; detailed integration strategies prepared. Target completion before end of FY27 subject to customary approvals. European acquisition to broaden technology offering and customer reach; Saudi acquisition to deepen local execution capability. Capital allocated deliberately - not asking subsidiaries to grow on thin balance sheets.
Digital Transformation: Deploying 3D modeling and AI integration across design-to-commissioning workflow to reduce turnaround time. Technology adoption aimed at operational excellence and procurement discipline for higher-value projects.
Capital Allocation Philosophy: Working capital released only against order book growth and real project requirements. Acquisitions based on strategic/integration fit, not structural growth assumptions. Idle capital held in FT with scalable growth; quarterly board reviews of active cash flow. IPO proceeds deployed to strengthen subsidiary balance sheets and negotiate better banking terms.
Margin Governance: Contribution margin (46.7%) now a governing metric for order selection - prioritizing quality over volume. Gross margin expansion levers: China procurement (where clients comfortable) + operating leverage from fixed cost control as top line scales.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Full Year Organic Revenue Growth | 20-25% YoY | H2-weighted execution; Q2 steady, significant acceleration in Q3/Q4 as deferred orders finalize |
| PAT Margin | 9-11% for FY27 | With ~25% revenue growth; Q1 at ~5.6% PAT margin but H2 seasonality drives full-year target |
| Order Book Conversion | Several large orders in Q2-Q3 | Geopolitical delays on donor/government funding cycles; no cancellations, client engagement active |
| Long-term Top Line | ₹1,000+ crores by 2030 | Organic growth target; internal communication benchmark |
| Accounting Method Transition | Gradual over next few years | Evaluating percentage-of-completion for new contracts; requires contract restructuring and auditor alignment |
| Acquisition Closure | Both Italy & Saudi before FY27 end | Subject to customary approvals; integration plans ready for fastest transition |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical Instability (Middle East War) | Ongoing conflict causing order conversion delays (not cancellations) and shipment availability issues; freight costs sharply increased; UAE execution normalization timeline uncertain - management stated "would not be able to answer till we speak to the president of the US" |
| Working Capital Pressure from Shipment Delays | ₹20-22 crores goods stuck at port due to vessel unavailability; receivables elevated at ₹215 crores with 10-15% locked in 1-2 year retention; LC terms at sight but 30-40 days transit adds to cycle |
| UAE Market Concentration Risk | Despite diversification, 70%+ revenue from MENA/GCC; UAE weakness cyclical vs structural unclear - population small, investing in high-tech not generic pharma; large pharma projects delayed by regional volatility |
| Market Perception / Stock Price Disconnect | Trading below IPO price despite profitable execution; institutional participation limited by market cap thresholds (<₹1,000 crore); management acknowledged "painful" but focused on fundamentals over sentiment |
| Acquisition Integration Execution | Two concurrent cross-border acquisitions (Italy, Saudi) with FY27 closure target; integration risk across technology, culture, and local regulatory compliance; capital deployment of ₹24+ crores committed |
Q&A Highlights
Institutional Participation & Stock Price
- Question: Concrete time-bound steps to improve institutional participation and restore investor confidence given stock below IPO price (Vikas Gupta)
- Answer: Management engages investors regularly but cannot control stock price; focused on profitable growth and substance over sentiment; open to investor introductions; IR/PR media coverage strategy being enhanced (Karan Doshi, Aman Anavkar)
Receivables & Cash Conversion
- Question: Receivables aging breakdown (contractual vs overdue) and cash conversion expectations for FY27 (Chandrashekhar Daga)
- Answer: Mostly LC/CAD backed; elevation due to 10-15% retention (1-2 years) and 30-40 day transit; Saudi large contract (₹120 crore) receivables tied to shipment milestones - collections expected from Q3 as deliveries complete (Karan Doshi)
Five-Year Strategic Vision & KPIs
- Question: Key strategic decisions/milestones for 5-year outperformance and quarterly measurable indicators (Raju Pathak)
- Answer: Positioned in structural growth markets (Africa, Saudi, SE Asia); deliberate decisions on talent, localization, volatility protection; measurable indicators: order book quality, hot lead conversion, contribution margin governance, acquisition integration progress (Aman Anavkar)
UAE Weakness Nature & Normalization
- Question: Is UAE weakness cyclical, customer-specific or industry-wide? When will execution normalize? (Chandrashekhar Daga)
- Answer: UAE investing in high-tech (cell/gene, medical devices) not generic pharma; large pharma projects in hot pipeline delayed by geopolitics; normalization timeline uncertain; UAE remains critical reference hub for international client visits (Aman Anavkar)
Order Book Composition & Repeat Business
- Question: Segment split (vaccines/biotech/pharma) and repeat customer percentage (Chandrashekhar Daga)
- Answer: Majority pharma/biotech; vaccines growing (Botswana, Saudi BioBago, 3 more Africa vaccine projects in negotiation); 10% revenue from repeat customers - actively reduced dependence to diversify portfolio; new projects become future repeat base (Karan Doshi, Aman Anavkar)
West Asia War Impact on Execution & Working Capital
- Question: Execution slowdown due to war? Working capital trajectory in normalized environment? (Vignesh Iyer)
- Answer: On-site execution continued (teams already deployed in Iraq, Saudi, Oman, Bahrain, UAE); conversion slowed as investors delayed decisions; working capital cycle ~120 days normalized; ₹110 cr advances offset receivables; labor largely outsourced providing flexibility (Aman Anavkar, Karan Doshi)
Contract Structure & Escalation Clauses
- Question: Tender nature (private vs government) and raw material escalation mechanisms (Vignesh Iyer)
- Answer: Mix of private tenders (RFP with technical/commercial evaluation) and government (L1/T1); some direct negotiations based on references; contracts have >5% RMC increase pass-through clauses; offers valid only 2-3 weeks; partnership approach ensures mutual timeline/cash flow alignment (Aman Anavkar)
IPO Proceeds & Inorganic Growth Progress
- Question: Progress on inorganic growth opportunities funded by IPO proceeds (Niraj Chhajer)
- Answer: Saudi acquisition (Specialized Contracting Activities) completed ~1.5 months ago - already secured civil order; European acquisition in due diligence - "better to know who you're marrying"; target closure next 2-3 quarters (Aman Anavkar)
Accounting Method Transition
- Question: Progress on shifting from milestone-based to percentage-of-completion accounting (Niraj Chhajer)